HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[New anti-angiogenic strategies in the management of kidney cancer].

AbstractINTRODUCTION:
The aim of this study was to clarify the current role of adjuvant and neo-adjuvant in the treatment of kidney cancer.
MATERIALS AND METHODS:
The data were explored in Medline (http://www.ncbi.nlm.nih.gov) using the following MeSH terms or combinations of these keywords: "cancer", "rein", "kidney", "adjuvant", "neoadjuvant", "antiangiogenique", "antiangiogenic" and selecting the items produced in their methodology, their relevance to the theme explored and their date of publication.
RESULTS:
Thirty-two English and French items published between 2001 and 2011 were selected: five studies of evidence level 1, nine level 2 studies, nine level 4 studies, five studies at level 5 and four literature reviews. The cytoreductive nephrectomy as first-line treatment of locally advanced or metastatic kidney cancer is now controversial with the advent of new targeted anti-angiogenic therapies. In neoadjuvant setting, these treatments showed a moderate decrease in tumor volume and rarely improved resectability. In adjuvant setting, their place has yet to be specified and several trials are currently underway.
CONCLUSION:
Recent years have seen the anti-angiogenic therapeutic strategies upset in locally advanced and metastatic renal cancer. The development of clinical trials and research protocols will allow us to determine in the near future the optimal therapeutic sequences.
AuthorsJ Drai, G Pignot, T Bessede, F Boulière, Y Hammoudi, S Ferlicot, J J Patard
JournalProgres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 23 Issue 10 Pg. 841-8 (Sep 2013) ISSN: 1166-7087 [Print] France
Vernacular TitleNouvelles stratégies anti-angiogéniques dans la prise en charge du cancer du rein.
PMID24034795 (Publication Type: English Abstract, Journal Article, Review)
CopyrightCopyright © 2013. Published by Elsevier Masson SAS.
Chemical References
  • Angiogenesis Inhibitors
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Humans
  • Kidney Neoplasms (blood supply, therapy)
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Nephrectomy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: